Clinical-stage Australian biotechnology company Immutep (ASX:IMM) has completed enrolment in the investigator-initiated EFTISARC-NEO trial. …
Immutep completes patient enrolment for EFTISARC-NEO Phase 2 trial
January 22, 2025 Australian Biotech
Latest Video
New Stories
-
Immutep completes patient enrolment for EFTISARC-NEO Phase 2 trial
January 22, 2025 - - Australian Biotech -
Emyria announces key leadership changes
January 22, 2025 - - Latest News -
Island Pharmaceuticals says all subjects now enrolled in key arm PROTECT clinical trial
January 22, 2025 - - Australian Biotech -
LTR Pharma signs national pharmacy distribution agreement with Symbion
January 22, 2025 - - BioPharma -
Make the case against the state's imposition of economic interests as the only consideration
January 21, 2025 - - Latest News -
BioCina and NovaCina merger aims to bolster the global CDMO industry
January 21, 2025 - - Australian Biotech -
Australian company Vaxxas named stage winner of US prize to advance vaccine patches
January 20, 2025 - - Australian Biotech